Final Results of the Sunbelt Melanoma trial: A multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy

Journal of Clinical Oncology

Volumn 34, Issue 10, 2016, Pages 1079-1086

  McMasters, Kelly M ^a   Egger, Michael E ^a   Edwards, Michael J ^d   Ross, Merrick I ^e   Reintgen, Douglas S ^g   Noyes, R Dirk ^h   Martin II, Robert C G ^a   Goydos, James S ⁱ   Beitsch, Peter D ^f   Urist, Marshall M ^j   Ariyan, Stephan ^k   Sussman, Jeffrey J ^d   Davidson, B Scott ^l   Gershenwald, Jeffrey E ^e   Hagendoorn, Lee J ^c   Stromberg, Arnold J ^b   Scoggins, Charles R ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Advertek Inc   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Dallas Surgical Group   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h LDS HOSPITAL   (United States)

ⁱ RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^j UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l NORTHSIDE HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; TECHNETIUM SULFUR COLLOID TC 99M; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MALE; MULTICENTER STUDY; NORTH AMERICA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; AGED; CLINICAL TRIAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MELANOMA; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; TREATMENT OUTCOME; WATCHFUL WAITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84962285552     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.3776     Document Type: Article

References (15)

1. Balch CM, Soong SJ, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of 1 to 4mmthick melanomas for patients 60 years of age and younger. Ann Surg 224:255-263 discussion 263-266, 1996;
2. Van der Velde-Zimmermann D, Roijers JF, Bouwens-Rombouts A, et al: Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 149:759-764, 1996
3. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
4. McMasters KM, Noyes RD, Reintgen DS, et al; Sunbelt Melanoma Trial: Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 86:212-223, 2004
5. Scoggins CR, Ross MI, Reintgen DS, et al: Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 24:2849-2857, 2006
6. Mellado B, Colomer D, Castel T, et al: Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis. J Clin Oncol 14:2091-2097, 1996
7. Miliotes G, Albertini J, Berman C, et al: The tumor biology of melanoma nodal metastases. Am Surg 62:81-88, 1996
8. Sarantou T, Chi DD, Garrison DA, et al: Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57:1371-1376, 1997
9. McMasters KM, Edwards MJ, Ross MI, et al: Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg 252:460-465 2010; discussion 465-466
10. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High-and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000
11. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
12. Eggermont AM, Suciu S, Rutkowski P, et al: Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: Results of the EORTC 18961 randomized phase III trial. J Clin Oncol 31:3831-3837, 2013
13. Mocellin S, Pasquali S, Rossi CR, et al: Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst 102:493-501, 2010
14. Morton DL, Thompson JF, Cochran AJ, et al; MSLT Group: Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599-609, 2014
15. Eggermont AM, Suciu S, Testori A, et al: Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48:218-225, 2012